As of 2026-05-31, the Fair Value of Immunitybio Inc (IBRX) is -4.16 USD. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 7.52 USD, the upside of Immunitybio Inc is -155.26%.
With the market price of 7.52 USD and our fair value calculation, Immunitybio Inc (IBRX) is not a good investment. Investing in IBRX stocks now will result in a potential loss of 155.26%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | 5Y Avg | |
| Net income | -346.79 | -416.57 | -583.20 | -413.56 | -351.40 | -422.30 |
| YoY growth | -56.32% | -20.12% | -40.00% | 29.09% | 15.03% | -14.46% |
| Market Cap (mil) | 7,731.39 |
| P/E | |
| Forward P/E |
| EPS | -0.83 |
| Avg earnings growth rate | -14.46% |
| TTM earnings | -854.53 |